A review about the potential role of follicle-stimulating hormone (FSH) in the development and progression of prostate cancer entitled “The Role of the FSH System in the Development and Progression of Prostate” was published in The American Journal of Hematology/Oncology by Dr. E. David Crawford, the distinguished Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus, and colleagues. This study highlights the associations between FSH, vascular endothelial growth factor (VEGF), and other key players involved in prostatic cancer, that could help decide the most appropriate type of prostate cancer treatment. The gonadotropin-releasing hormone (GnRH) and its control of the gonadal endocrine system through the regulation of FSH and luteinizing hormone (LH) and the effects on androgens, estrogens and the ovulatory cycle, was discovered and described by Dr. Andrew Schally, who receive